• United Therapeutics authorized a new buyback program for up to $2 billion of common stock, available through October 21, 2027.
• The existing accelerated share repurchase transaction, initiated in September 2026, will not reduce the new authorization.
• That transaction is scheduled to end in the fourth quarter of 2026, subject to early termination or extension.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202610220700BIZWIRE_USPR_____20261022_BW071884) on October 22, 2026, and is solely responsible for the information contained therein.